Navigation Links
Study finds that drugs used for treatment of influenza in pregnancy appear to be safe
Date:4/27/2010

DALLAS April 29, 2010 Tamiflu and two other drugs used to treat influenza appear safe for pregnant women and their babies, researchers at UT Southwestern Medical Center have found in a retrospective study of 239 cases of women who received the medications during pregnancy.

The study provides "reassuring safety data about commonly used medications," the researchers concluded in their study, which appears in the April issue of Obstetrics and Gynecology.

"A woman has to balance the benefits and potential risks of any medication taken during pregnancy. But with influenza, the added risks of complications from the disease in pregnancy need to be considered," said Dr. George Wendel, professor of obstetrics and gynecology at UT Southwestern and senior author of the study.

"This is the first large study that systematically looked at the safety of all these drugs in pregnancy," he said.

Researchers analyzed the medical records of 82,336 women who gave birth at Parkland Memorial Hospital from 2003 to 2008, a period that spanned five flu seasons. The investigators compared two groups of pregnant women: women without flu and women with flu who had received one of three oral medications marketed under the brands Tamiflu, Relenza and Flumadine. Of the women studied, 239 had flu and had been treated with one of the three medications.

The study showed no difference in the mothers' rates of preeclampsia, preterm birth, gestational diabetes, premature membrane rupture, fever during labor or prolonged hospital stay.

After birth, there was no difference in birth weight, need for intensive care, seizures or jaundice among the babies. There also was no significant difference in stillbirths or major or minor malformations that could be attributed to the medications, the study showed.

The only significant difference involved a bowel condition, necrotizing enterocolitis, often associated with prematurity. Two premature babies in the treatment group were born with this condition. Each of the mothers, however, received a different anti-flu drug, so the prematurity may have been the major common factor, said Dr. Laura Greer, assistant instructor of obstetrics and gynecology and lead author of the paper.

One limitation of study was that only 13 percent of the women with flu were treated during the first trimester, a critical time in fetal development. "Overall, this study provides important safety data to guide clinicians and patients in treating influenza in pregnancy," Dr. Greer said.

The data collection stopped a year before the pandemic H1N1 flu strain, or swine flu, became widespread. Tamiflu was used in 2009 to treat pandemic H1N1 infection, a type of influenza A; it is also effective in treating seasonal influenza A and B infection. The other two medications were more commonly used in earlier influenza seasons.


'/>"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Comparative-effectiveness study confirms new treatment for diabetic macular edema
2. CureTogether Announces Online Autism Treatment Study
3. LA BioMed awarded research grant to study HIV prevention gel
4. Study Makes Strides in Understanding Ovarian Cancer
5. Brown Rice Tied to Better Heart Health in Study
6. NIH study confirms location of stem cells near cartilage-rich regions in bones
7. Immune cells predict success of head and neck cancer treatment, U-M study finds
8. Noncardiac Chest Pain May Warrant More Management: Study
9. SGIC Study Finds Drivers Are Losing Their Cool At School
10. Health impacts of mobile phone use to be explored in huge new study
11. Study of Williams syndrome patients reveals specific genes role in intelligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... TX (PRWEB) , ... September 20, 2017 , ... ... date of the much-anticipated fall event , Look Awesome This Autumn with ... personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique is ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that Clear Global ... support services market) has entered into an agreement on September 1, 2017 with ... PGSD is the first private Dental School to launch an online, accredited Post ...
(Date:9/20/2017)... ... , ... Compliancy Group is proud to announce that its ... another long-time client pass their Department of Health and Human Services (HHS) Office ... to the help of the Compliancy Group's Audit Response Program™, not a single ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods ... market impact in 27 different categories. Nopavera Plus was named to the ... be announced at SupplySide West 2017 during presentations at SupplySide Central on Sept. 27 ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: